Search Results

You are looking at 1 - 4 of 4 items for :

  • T regulatory cell x
  • Paediatric Haematology and Oncology x
Clear All
Open access

Aneta Malesa, Justyna Nowak, Katarzyna Skórka, Marta Karp and Krzysztof Giannopoulos

, Thomson AW. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol. 2006;176(5):2808–16. 10.4049/jimmunol.176.5.2808 Raimondi G Shufesky WJ Tokita D Morelli AE Thomson AW Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells J Immunol 2006 176 5 2808 – 16 [19] Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development

Open access

Mateusz Nowicki, Piotr Stelmach and Anna Szmigielska-Kapłon

decreased expression of major histocompatibility complex (MHC) II antigens, which in turn impairs the function of T-lymphocytes [ 20 ]. This process is associated with decreased activity of NK-κB signaling pathway [ 8 ]. VEGF significantly regulates proliferation and migration of EC. By recruiting HSC and endothelial progenitor cells VEGF regulates microvessels development in the bone marrow niche and fundamentally affects hematopoiesis [ 15 , 21 ]. ANGPT1 and ANGPT2 Apart from VEGF, angiopoietin 1 (ANGPT1) and angiopoietin 2 (ANGPT2), both binding to receptor

Open access

Samia Abd El-Moneim Ebied, Nadia Aly Sadek, Nadia El-Sayed Zaki, Samir Ali Abd El- Kaream and Heba Khafagui Ahmed El Kashif

accumulation of blast cells in the bone marrow and peripheral blood [ 12 ]. Acute lymphoblastic leukemia (ALL) is a malignant disease characterized by the accumulation of lymphoblasts and it may be B or T lineages and the first attempt at classifying ALL was the French-American-British (FAB) morphological criteria that divided ALL into 3 subtypes (L1, L2 and L3) based on cell size, cytoplasm, nucleoli, vacuolation and basophilia. In 1997, the World Health Organization proposed a composite classification in an attempt to account for morphology and cytogenetic profile of the

Open access

Iga Andrasiak and Tomasz Wróbel

European Congress, 02/11/2016, Vienna. Schmitter S Brock E Holzerny P Günzel CA Ruckdäschel S Regulatory Agencies’ Perspective on “Progression-Free Survival” (PFS), Poster-No. PCN289, ISPOR 19th Annual European Congress, 02/11/2016 Vienna [10] Ishikawa T, Akazawa K, Hasegawa Y, et al. Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer. J Surg Res 2017;220:46–51. 10.1016/j.jss.2017.05.066 Ishikawa T Akazawa K Hasegawa Y Survival outcomes of neoadjuvant chemotherapy with zoledronic acid